Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724107 | SCV000225329 | uncertain significance | not provided | 2014-07-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000174091 | SCV000526271 | likely benign | not specified | 2016-03-28 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001451060 | SCV001654679 | likely benign | Duchenne muscular dystrophy | 2024-09-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002453608 | SCV002614225 | uncertain significance | Cardiovascular phenotype | 2021-09-07 | criteria provided, single submitter | clinical testing | The c.1150-4T>A intronic variant results from a T to A substitution 4 nucleotides upstream from coding exon 11 in the DMD gene. Based on data from gnomAD, the A allele has an overall frequency of 0.001097% (2/182391) total alleles studied, with 1 hemizygote(s) observed. The highest observed frequency was 0.006318% (1/15827) of European (Finnish) alleles. This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001826874 | SCV002090402 | likely benign | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2018-05-04 | no assertion criteria provided | clinical testing |